Clinical Scorecard: Colorectal Cancer Treatment During Pregnancy

At a Glance

Key Highlights

• 1 in 13,000 pregnancies affected by CRC, with increasing incidence due to delayed childbearing.
• Median age at CRC diagnosis in pregnant women is 32 years.
• 48% of CRC diagnoses in pregnancy are metastatic at presentation.
• Imaging choices must balance fetal safety with diagnostic needs.
• Chemotherapy is generally avoided in the first trimester due to teratogenic risks.

Guideline-Based Recommendations

Diagnosis

• Use ultrasound and MRI for imaging when possible to avoid ionizing radiation.
• Consider colonoscopy with caution due to potential risks to the fetus.

Management

• Multidisciplinary discussions are essential for treatment planning.
• Avoid chemotherapy in the first trimester; consider risks in later trimesters.

Monitoring & Follow-up

• Regular monitoring of tumor markers and imaging as needed based on clinical status.

Risks

• Potential for congenital malformations and organ impairment if chemotherapy is administered in the first trimester.
• Risks of prematurity and intrauterine growth restriction in later trimesters.

Patient & Prescribing Data

Pregnant women with colorectal cancer.

Standard dosing based on maternal body weight is recommended; fetal exposure to drugs varies.

Clinical Best Practices

• Engage in multidisciplinary care for complex cases.
• Assess the timing of treatment based on gestational age and cancer stage.
• Prioritize non-ionizing imaging methods for diagnosis.

References

• Siegel et al., 2026
• Fidler et al., 2017
• Salani et al., 2014
• Rogers et al., 2016
• Peccatori et al., 2013